Phase 2 Endometrial Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been fully informed about the study and have voluntarily signed and dated a consent form before the study begins.
• People aged 18 years or older at the time of signing the consent form.
• People whose body weight falls within a healthy range, specifically a Body Mass Index (BMI) between 18 and 32 kg/m².
• People who have been diagnosed with a specific type of advanced cancer — including certain types of lung cancer (non-squamous non-small cell), colorectal cancer, cervical cancer, or other advanced solid tumours — confirmed by laboratory testing of tissue, and who have already received one or two rounds of treatment for their advanced or metastatic disease.
• People who have at least one measurable tumour site outside the brain that can be tracked during the study, according to standard measurement guidelines.
• People for whom stored or freshly collected tumour tissue samples are available for testing.
• People whose general health and ability to carry out daily activities is rated at a level of 0 or 1 on a standard medical scale (meaning fully active or restricted in strenuous activity only).
• People whose organ and bone marrow function meet the study's required levels within 7 days before the first dose.
• People who agree to use highly effective contraception from the screening period through to at least 6 months after the last dose of the study drug — this applies to both women who could become pregnant and to men.
• People who are expected to live for at least 3 months.
• People who are able and willing to attend all required study visits and follow all study procedures.

Who may not be able to join:

• People who have previously received any drug treatment that specifically targeted a protein called HER3.
• People who have previously had an intolerance to a class of cancer drugs called topoisomerase I inhibitors, or to a type of drug delivery treatment (called an antibody-drug conjugate) that uses this class of drug.
• People who are currently taking part in another interventional clinical trial (participation in non-interventional observational studies or being in a follow-up phase of a completed trial may be acceptable — confirm with trial site).
• People who have not waited long enough after their last cancer treatment before starting this study, as required by the study guidelines (confirm with trial site for specific timeframes).
• People who have had major surgery (not including minor diagnostic procedures) within 4 weeks before the first dose, or who are expected to need major surgery during the study.
• People who have previously received a bone marrow transplant from a donor, or a transplanted solid organ.
• People who have taken systemic steroid medications above a certain dose, or other medicines that suppress the immune system, within 2 weeks before the first dose.
• People who have received a live vaccine within 4 weeks before the first dose, or who plan to receive one during the study.
• People whose cancer has spread to the membranes surrounding the brain or spinal cord.
• People who have cancer that has spread to the brain, or who have spinal cord compression caused by cancer.
• People with significant or uncontrolled heart or blood vessel disease.
• People with significant or complicated lung conditions.
• People who have had a history of a brain condition related to liver failure (hepatic encephalopathy) within 6 months before the first dose.
• People with active or ongoing eye or cornea conditions that require continuous treatment, or corneal conditions that would make it difficult to safely monitor the effects of the study drug on the eyes.
• People who have been diagnosed with a genetic condition called Gilbert's syndrome, which affects how the body processes a substance called bilirubin.
• People with significant fluid build-up around the lungs, abdomen, or heart that is causing symptoms, is unstable, or requires repeated draining.
• People who have had a history of a hole or abnormal opening forming in the gastrointestinal tract within 6 months before the first dose, or who have active stomach or bowel conditions that carry a significant risk of bleeding or perforation.
• People who have had a serious infection before the first dose (confirm with trial site for specific severity grading).
• People with serious blood clotting disorders or other conditions that carry a clear risk of significant bleeding.
• People with diabetes that is not well controlled.
• People with HIV infection, or who test positive for syphilis with a confirmed positive level result.
• People with an active hepatitis B or hepatitis C infection.
• People who have had another primary cancer diagnosed within the past 5 years, except for certain fully treated skin cancers, cured localised cancers, or other solid tumours considered fully cured.
• People who still have unresolved side effects from previous cancer treatment.
• People with a history of severe allergic reactions to ingredients in the study drug or to other similar medicines (monoclonal antibodies).
• Women who are breastfeeding, or women who test positive on a pregnancy test within 3 days before the first dose.
• People who have any medical, psychological, or social circumstances — including mental illness or substance or alcohol misuse — that in the treating doctor's opinion could affect their ability to consent, participate fully, or would make the study results difficult to interpret.

Important: Always verify eligibility with the trial site directly before applying.